MedTrace Logo

The Epidemiology of Patients Treated With ATZ+BEV in Real Life Setting

NCT06903663 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-04-17

No results posted yet for this study

Summary

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death globally.

This retrospective, multicentric study will be coordinated by Dr. Adrian Radu Vidra (Lead Investigator) from Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor" Cluj-Napoca (Coordinating Site) to further investigate the clinical and demographic profile of patients receiving first-line treatment with atezolizumab and bevacizumab in the real-world setting of clinical practice from Romania.

Participants already taking the combination therapy as part of their regular medical care for HCC will be followed during 3 years.

Conditions

  • Hepatocellular Carcinoma (HCC)

Sponsors & Collaborators

  • MDX Research

    collaborator NETWORK

  • Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor

    lead OTHER

Principal Investigators

  • Adrian Radu Vidra · Regional Institute of Gastroenterology and Hepatology "Prof. Dr. Octavian Fodor" Cluj-Napoca

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2025-07-31
Completion
2025-12-31

Countries

  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06903663 on ClinicalTrials.gov